Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 57 | 2024 | 1560 | 6.850 |
Why?
|
Leukemia, Myeloid, Acute | 98 | 2024 | 3626 | 5.950 |
Why?
|
Mastocytosis, Systemic | 12 | 2023 | 102 | 5.090 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 29 | 2024 | 686 | 3.870 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 12 | 2024 | 37 | 2.730 |
Why?
|
Myelodysplastic Syndromes | 29 | 2024 | 1399 | 2.450 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 47 | 2024 | 11873 | 2.100 |
Why?
|
Triazines | 7 | 2023 | 311 | 2.030 |
Why?
|
Antineoplastic Agents | 67 | 2024 | 13658 | 2.020 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2024 | 230 | 1.910 |
Why?
|
Protein Kinase Inhibitors | 38 | 2024 | 5694 | 1.830 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2024 | 384 | 1.750 |
Why?
|
Pyrroles | 11 | 2023 | 1123 | 1.670 |
Why?
|
Pyrimidines | 21 | 2022 | 3046 | 1.620 |
Why?
|
fms-Like Tyrosine Kinase 3 | 18 | 2023 | 494 | 1.510 |
Why?
|
Remission Induction | 42 | 2024 | 2409 | 1.510 |
Why?
|
Staurosporine | 9 | 2017 | 241 | 1.480 |
Why?
|
Asparaginase | 10 | 2024 | 240 | 1.330 |
Why?
|
Hematologic Neoplasms | 14 | 2024 | 1907 | 1.290 |
Why?
|
Pyrazoles | 10 | 2024 | 2028 | 1.200 |
Why?
|
Cytarabine | 19 | 2024 | 695 | 1.150 |
Why?
|
Mastocytosis | 4 | 2023 | 150 | 1.110 |
Why?
|
Piperazines | 15 | 2016 | 2552 | 1.110 |
Why?
|
Leukemia, Promyelocytic, Acute | 5 | 2020 | 249 | 1.080 |
Why?
|
Sulfonamides | 15 | 2024 | 1982 | 0.990 |
Why?
|
Myeloproliferative Disorders | 11 | 2023 | 616 | 0.940 |
Why?
|
Drug Resistance, Neoplasm | 28 | 2024 | 5335 | 0.890 |
Why?
|
Pyridazines | 6 | 2024 | 203 | 0.880 |
Why?
|
Neoplasm, Residual | 12 | 2024 | 1014 | 0.870 |
Why?
|
Protein-Tyrosine Kinases | 10 | 2018 | 2428 | 0.820 |
Why?
|
Fusion Proteins, bcr-abl | 15 | 2024 | 430 | 0.820 |
Why?
|
Salvage Therapy | 9 | 2022 | 1273 | 0.800 |
Why?
|
Hydroxamic Acids | 5 | 2017 | 483 | 0.800 |
Why?
|
Thrombocythemia, Essential | 3 | 2024 | 114 | 0.780 |
Why?
|
Hematopoietic Stem Cell Transplantation | 23 | 2024 | 5717 | 0.770 |
Why?
|
Drug Substitution | 2 | 2014 | 291 | 0.740 |
Why?
|
Glycolipids | 1 | 2022 | 205 | 0.740 |
Why?
|
Arabinonucleosides | 3 | 2014 | 34 | 0.740 |
Why?
|
Disease-Free Survival | 29 | 2024 | 6843 | 0.730 |
Why?
|
Philadelphia Chromosome | 13 | 2024 | 119 | 0.720 |
Why?
|
Histone Deacetylase Inhibitors | 5 | 2013 | 777 | 0.720 |
Why?
|
Mutation | 43 | 2024 | 30211 | 0.710 |
Why?
|
Thiazoles | 4 | 2014 | 1542 | 0.700 |
Why?
|
Proto-Oncogene Proteins c-kit | 7 | 2022 | 723 | 0.690 |
Why?
|
Recurrence | 30 | 2024 | 8507 | 0.680 |
Why?
|
Cyclopentanes | 2 | 2017 | 87 | 0.660 |
Why?
|
Immunotherapy, Adoptive | 7 | 2024 | 1512 | 0.660 |
Why?
|
Humans | 296 | 2024 | 767991 | 0.660 |
Why?
|
Nitriles | 5 | 2018 | 980 | 0.650 |
Why?
|
Aniline Compounds | 4 | 2018 | 1094 | 0.620 |
Why?
|
Benzazepines | 1 | 2020 | 308 | 0.610 |
Why?
|
Aged | 115 | 2024 | 171446 | 0.610 |
Why?
|
Quinolines | 3 | 2018 | 770 | 0.600 |
Why?
|
Leukemia, Myeloid | 9 | 2019 | 693 | 0.600 |
Why?
|
Adult | 128 | 2024 | 223583 | 0.600 |
Why?
|
Dexamethasone | 3 | 2020 | 1964 | 0.590 |
Why?
|
Maximum Tolerated Dose | 13 | 2022 | 897 | 0.590 |
Why?
|
Benzamides | 12 | 2013 | 1377 | 0.590 |
Why?
|
Enzyme Inhibitors | 10 | 2022 | 3726 | 0.590 |
Why?
|
Leukemia | 9 | 2024 | 1519 | 0.580 |
Why?
|
Imidazoles | 7 | 2024 | 1168 | 0.580 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2022 | 9412 | 0.570 |
Why?
|
Middle Aged | 131 | 2024 | 223422 | 0.570 |
Why?
|
Polycythemia Vera | 3 | 2021 | 160 | 0.560 |
Why?
|
Bone Marrow | 15 | 2024 | 2935 | 0.550 |
Why?
|
Antigens, CD19 | 5 | 2024 | 446 | 0.540 |
Why?
|
Indoles | 6 | 2017 | 1835 | 0.530 |
Why?
|
Janus Kinase 2 | 9 | 2021 | 561 | 0.520 |
Why?
|
Quinazolines | 4 | 2013 | 1369 | 0.500 |
Why?
|
Treatment Outcome | 59 | 2024 | 65364 | 0.480 |
Why?
|
Male | 147 | 2024 | 364641 | 0.470 |
Why?
|
Survival Rate | 29 | 2024 | 12828 | 0.450 |
Why?
|
Female | 145 | 2024 | 397113 | 0.450 |
Why?
|
Aged, 80 and over | 53 | 2024 | 59598 | 0.450 |
Why?
|
Recombinant Fusion Proteins | 3 | 2024 | 3740 | 0.440 |
Why?
|
Primary Myelofibrosis | 2 | 2013 | 209 | 0.430 |
Why?
|
Thiazolidines | 4 | 2018 | 70 | 0.420 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 4 | 2018 | 93 | 0.420 |
Why?
|
Etoposide | 6 | 2022 | 640 | 0.420 |
Why?
|
Young Adult | 54 | 2024 | 60048 | 0.420 |
Why?
|
Niacinamide | 4 | 2024 | 418 | 0.410 |
Why?
|
Hepatic Veno-Occlusive Disease | 4 | 2019 | 220 | 0.410 |
Why?
|
Dose-Response Relationship, Drug | 15 | 2022 | 10757 | 0.400 |
Why?
|
Prognosis | 37 | 2024 | 29979 | 0.400 |
Why?
|
5'-Nucleotidase | 1 | 2013 | 164 | 0.380 |
Why?
|
Leukemia, Neutrophilic, Chronic | 2 | 2023 | 14 | 0.380 |
Why?
|
Mitoxantrone | 3 | 2022 | 148 | 0.380 |
Why?
|
Leukemic Infiltration | 3 | 2018 | 47 | 0.380 |
Why?
|
Neutropenia | 4 | 2024 | 892 | 0.370 |
Why?
|
Transplantation, Homologous | 17 | 2024 | 4833 | 0.360 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 3 | 2016 | 31 | 0.360 |
Why?
|
Anthracyclines | 4 | 2023 | 286 | 0.350 |
Why?
|
Immunoconjugates | 4 | 2024 | 975 | 0.340 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 2022 | 2510 | 0.340 |
Why?
|
Azacitidine | 6 | 2024 | 336 | 0.330 |
Why?
|
Molecular Targeted Therapy | 5 | 2023 | 2824 | 0.330 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 2 | 2007 | 168 | 0.330 |
Why?
|
Transplantation Conditioning | 8 | 2024 | 1601 | 0.330 |
Why?
|
Gene Expression Regulation, Leukemic | 6 | 2021 | 658 | 0.320 |
Why?
|
Biphenyl Compounds | 5 | 2018 | 1026 | 0.310 |
Why?
|
Apoptosis | 14 | 2019 | 9521 | 0.310 |
Why?
|
Isocitrate Dehydrogenase | 4 | 2024 | 951 | 0.300 |
Why?
|
Survival Analysis | 16 | 2024 | 10098 | 0.300 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2017 | 2568 | 0.300 |
Why?
|
Spinal Nerves | 1 | 2008 | 92 | 0.300 |
Why?
|
Nucleosides | 1 | 2008 | 130 | 0.290 |
Why?
|
Daunorubicin | 7 | 2024 | 157 | 0.290 |
Why?
|
T-Lymphocytes | 9 | 2024 | 10264 | 0.290 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2008 | 133 | 0.280 |
Why?
|
Hypereosinophilic Syndrome | 2 | 2005 | 97 | 0.280 |
Why?
|
Leukemia, Mast-Cell | 2 | 2017 | 13 | 0.270 |
Why?
|
Clinical Trials as Topic | 10 | 2024 | 8052 | 0.270 |
Why?
|
Aminoglycosides | 2 | 2006 | 161 | 0.270 |
Why?
|
Adolescent | 44 | 2024 | 89155 | 0.270 |
Why?
|
Tumor Lysis Syndrome | 2 | 2018 | 37 | 0.260 |
Why?
|
Urate Oxidase | 2 | 2018 | 31 | 0.260 |
Why?
|
Antibodies, Monoclonal | 5 | 2015 | 9252 | 0.260 |
Why?
|
Age Factors | 16 | 2022 | 18407 | 0.260 |
Why?
|
Thrombocytosis | 2 | 2024 | 88 | 0.250 |
Why?
|
Vincristine | 2 | 2020 | 1040 | 0.240 |
Why?
|
Drug Administration Schedule | 7 | 2014 | 4857 | 0.240 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2021 | 329 | 0.240 |
Why?
|
Antibodies, Bispecific | 2 | 2024 | 204 | 0.240 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 7 | 2024 | 1405 | 0.240 |
Why?
|
Tryptases | 2 | 2023 | 175 | 0.240 |
Why?
|
Bone Marrow Transplantation | 8 | 2016 | 2710 | 0.240 |
Why?
|
Stem Cell Transplantation | 6 | 2018 | 1596 | 0.230 |
Why?
|
Retrospective Studies | 35 | 2024 | 81746 | 0.230 |
Why?
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2016 | 10 | 0.230 |
Why?
|
Acute Disease | 13 | 2024 | 7241 | 0.230 |
Why?
|
Phenylurea Compounds | 2 | 2018 | 531 | 0.230 |
Why?
|
Mycoses | 2 | 2022 | 386 | 0.230 |
Why?
|
Immunophenotyping | 5 | 2021 | 1863 | 0.220 |
Why?
|
Aminopyridines | 3 | 2017 | 580 | 0.220 |
Why?
|
Glycogen Synthase Kinase 3 | 2 | 2018 | 414 | 0.210 |
Why?
|
Venous Thromboembolism | 4 | 2024 | 1883 | 0.210 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2021 | 639 | 0.210 |
Why?
|
Cytogenetics | 3 | 2010 | 198 | 0.210 |
Why?
|
Administration, Oral | 6 | 2017 | 4030 | 0.200 |
Why?
|
Burkitt Lymphoma | 1 | 2005 | 338 | 0.200 |
Why?
|
Lymphoma | 3 | 2023 | 1897 | 0.200 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 3 | 2017 | 355 | 0.200 |
Why?
|
Nuclear Proteins | 6 | 2024 | 5799 | 0.200 |
Why?
|
Cell Differentiation | 12 | 2021 | 11665 | 0.200 |
Why?
|
Neoplasms, Second Primary | 2 | 2024 | 1061 | 0.200 |
Why?
|
Myeloid Cells | 4 | 2015 | 839 | 0.200 |
Why?
|
Neoplasms | 12 | 2022 | 22365 | 0.190 |
Why?
|
Treatment Failure | 4 | 2019 | 2660 | 0.190 |
Why?
|
Benzimidazoles | 2 | 2018 | 863 | 0.190 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2022 | 187 | 0.190 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 3 | 2017 | 367 | 0.190 |
Why?
|
Cancer Care Facilities | 1 | 2024 | 427 | 0.190 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 308 | 0.190 |
Why?
|
Chromosomes, Human, Pair 5 | 3 | 2008 | 386 | 0.190 |
Why?
|
DNA-Binding Proteins | 6 | 2024 | 9614 | 0.180 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2019 | 1374 | 0.180 |
Why?
|
Methotrexate | 3 | 2014 | 1721 | 0.180 |
Why?
|
Doxorubicin | 2 | 2020 | 2234 | 0.180 |
Why?
|
Receptor Protein-Tyrosine Kinases | 6 | 2022 | 1621 | 0.180 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2023 | 263 | 0.180 |
Why?
|
Mitochondria | 6 | 2019 | 3681 | 0.180 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 7445 | 0.180 |
Why?
|
Histones | 5 | 2013 | 2600 | 0.180 |
Why?
|
Chromosome Deletion | 5 | 2006 | 1384 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2021 | 3609 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 7 | 2024 | 6517 | 0.170 |
Why?
|
Follow-Up Studies | 16 | 2024 | 39345 | 0.170 |
Why?
|
Osteonecrosis | 1 | 2022 | 230 | 0.170 |
Why?
|
Medical Oncology | 5 | 2024 | 2341 | 0.170 |
Why?
|
Uric Acid | 2 | 2018 | 805 | 0.170 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2017 | 2846 | 0.160 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2015 | 422 | 0.160 |
Why?
|
Cyclophosphamide | 2 | 2020 | 2227 | 0.160 |
Why?
|
Tandem Repeat Sequences | 3 | 2016 | 183 | 0.160 |
Why?
|
Flow Cytometry | 7 | 2018 | 5902 | 0.160 |
Why?
|
Cancer Vaccines | 3 | 2016 | 1041 | 0.160 |
Why?
|
Leukemia, Experimental | 2 | 2016 | 225 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 724 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 7 | 2015 | 4525 | 0.160 |
Why?
|
Immunotherapy | 5 | 2024 | 4748 | 0.160 |
Why?
|
Bone Marrow Examination | 3 | 2018 | 154 | 0.160 |
Why?
|
Chromosome Aberrations | 3 | 2019 | 1777 | 0.160 |
Why?
|
Standard of Care | 2 | 2022 | 568 | 0.150 |
Why?
|
Enhancer Elements, Genetic | 3 | 1995 | 1367 | 0.150 |
Why?
|
Hepatitis B | 1 | 2024 | 711 | 0.150 |
Why?
|
Galectins | 1 | 2021 | 295 | 0.150 |
Why?
|
Histiocytes | 1 | 2018 | 97 | 0.150 |
Why?
|
Cell Proliferation | 11 | 2021 | 10470 | 0.150 |
Why?
|
Hydrazines | 2 | 2009 | 223 | 0.150 |
Why?
|
Thrombosis | 4 | 2024 | 2957 | 0.150 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2014 | 2889 | 0.150 |
Why?
|
Inhibitory Concentration 50 | 4 | 2016 | 464 | 0.150 |
Why?
|
Langerhans Cells | 1 | 2018 | 169 | 0.150 |
Why?
|
Karyotyping | 4 | 2014 | 1176 | 0.150 |
Why?
|
Arterial Occlusive Diseases | 1 | 2022 | 744 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.140 |
Why?
|
Mast Cells | 3 | 2023 | 1405 | 0.140 |
Why?
|
Translocation, Genetic | 5 | 2020 | 1390 | 0.140 |
Why?
|
Immune Evasion | 1 | 2021 | 375 | 0.140 |
Why?
|
Graft vs Host Disease | 6 | 2024 | 3049 | 0.140 |
Why?
|
Ubiquitin-Activating Enzymes | 2 | 2015 | 85 | 0.140 |
Why?
|
Eosinophilia | 1 | 2022 | 554 | 0.140 |
Why?
|
Cytogenetic Analysis | 3 | 2013 | 270 | 0.140 |
Why?
|
Premedication | 1 | 2018 | 245 | 0.140 |
Why?
|
Neoplastic Stem Cells | 3 | 2021 | 1351 | 0.140 |
Why?
|
Hemorrhage | 3 | 2024 | 3467 | 0.140 |
Why?
|
Leukemia, Hairy Cell | 1 | 2017 | 82 | 0.140 |
Why?
|
Methenyltetrahydrofolate Cyclohydrolase | 1 | 2016 | 10 | 0.140 |
Why?
|
Gout Suppressants | 1 | 2018 | 176 | 0.140 |
Why?
|
Incidence | 12 | 2024 | 21532 | 0.130 |
Why?
|
Geriatric Assessment | 2 | 2015 | 1422 | 0.130 |
Why?
|
Cell Line, Tumor | 15 | 2021 | 17128 | 0.130 |
Why?
|
Telomerase | 1 | 2021 | 751 | 0.130 |
Why?
|
Leukocytes, Mononuclear | 3 | 2021 | 1854 | 0.130 |
Why?
|
Phosphorylation | 10 | 2017 | 8314 | 0.130 |
Why?
|
Proto-Oncogenes | 1 | 2017 | 321 | 0.130 |
Why?
|
Anaphylaxis | 1 | 2023 | 755 | 0.130 |
Why?
|
U937 Cells | 5 | 2018 | 260 | 0.130 |
Why?
|
Leukemia, T-Cell | 1 | 2016 | 102 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2014 | 646 | 0.130 |
Why?
|
RecQ Helicases | 1 | 2015 | 53 | 0.130 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 8 | 2015 | 4576 | 0.130 |
Why?
|
TYK2 Kinase | 1 | 2015 | 38 | 0.130 |
Why?
|
HL-60 Cells | 5 | 2017 | 364 | 0.130 |
Why?
|
Resorcinols | 1 | 2015 | 41 | 0.120 |
Why?
|
Glomerulonephritis | 1 | 2017 | 333 | 0.120 |
Why?
|
Tetrahydronaphthalenes | 1 | 2015 | 85 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 2014 | 7 | 0.120 |
Why?
|
Citric Acid Cycle | 1 | 2016 | 234 | 0.120 |
Why?
|
Receptors, Laminin | 1 | 2014 | 26 | 0.120 |
Why?
|
Tretinoin | 2 | 2020 | 524 | 0.120 |
Why?
|
Granulocyte Precursor Cells | 3 | 2016 | 49 | 0.120 |
Why?
|
Kidney Glomerulus | 1 | 2017 | 571 | 0.120 |
Why?
|
Creatine Kinase | 1 | 2017 | 684 | 0.120 |
Why?
|
Sirolimus | 2 | 2014 | 1538 | 0.120 |
Why?
|
Benzodiazepines | 2 | 2018 | 1138 | 0.120 |
Why?
|
Tumor Cells, Cultured | 8 | 2021 | 6119 | 0.120 |
Why?
|
Adenine Nucleotides | 1 | 2014 | 110 | 0.120 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 17 | 0.120 |
Why?
|
Cell Cycle Proteins | 2 | 2024 | 3443 | 0.120 |
Why?
|
bcl-X Protein | 2 | 2014 | 412 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 2061 | 0.120 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 260 | 0.120 |
Why?
|
Signal Transduction | 14 | 2023 | 23642 | 0.120 |
Why?
|
Cyclosporins | 2 | 2013 | 216 | 0.110 |
Why?
|
Long QT Syndrome | 1 | 2019 | 472 | 0.110 |
Why?
|
Receptors, IgG | 1 | 2017 | 564 | 0.110 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 2 | 2024 | 36 | 0.110 |
Why?
|
Brain Edema | 1 | 2018 | 601 | 0.110 |
Why?
|
Prescription Fees | 1 | 2015 | 153 | 0.110 |
Why?
|
Eukaryotic Initiation Factors | 1 | 2014 | 83 | 0.110 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2016 | 558 | 0.110 |
Why?
|
Receptor, Notch1 | 2 | 2015 | 518 | 0.110 |
Why?
|
Valine | 1 | 2015 | 410 | 0.110 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2016 | 337 | 0.110 |
Why?
|
Isoxazoles | 1 | 2015 | 233 | 0.110 |
Why?
|
Bone Marrow Cells | 4 | 2021 | 2414 | 0.110 |
Why?
|
Mice, SCID | 5 | 2022 | 2627 | 0.110 |
Why?
|
Receptor, Notch2 | 1 | 2014 | 90 | 0.110 |
Why?
|
Busulfan | 2 | 2021 | 259 | 0.110 |
Why?
|
Refrigeration | 1 | 2013 | 27 | 0.110 |
Why?
|
Gene Frequency | 2 | 2018 | 3623 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2009 | 1608 | 0.110 |
Why?
|
Acetylcysteine | 1 | 2014 | 262 | 0.110 |
Why?
|
Patient Selection | 3 | 2020 | 4258 | 0.110 |
Why?
|
Orthopedics | 1 | 2022 | 906 | 0.110 |
Why?
|
Vidarabine | 2 | 2021 | 337 | 0.110 |
Why?
|
Patient Advocacy | 1 | 2015 | 362 | 0.100 |
Why?
|
Blotting, Western | 7 | 2017 | 5024 | 0.100 |
Why?
|
Infection Control | 1 | 2020 | 985 | 0.100 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2014 | 1077 | 0.100 |
Why?
|
Mice | 25 | 2022 | 82024 | 0.100 |
Why?
|
Intention to Treat Analysis | 3 | 2019 | 416 | 0.100 |
Why?
|
Acetylation | 2 | 2013 | 1055 | 0.100 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 268 | 0.100 |
Why?
|
Combined Modality Therapy | 7 | 2022 | 8535 | 0.100 |
Why?
|
Infusions, Intravenous | 5 | 2024 | 2227 | 0.100 |
Why?
|
Megakaryocytes | 2 | 2015 | 571 | 0.100 |
Why?
|
Risk Factors | 17 | 2024 | 74936 | 0.100 |
Why?
|
DNA Methylation | 3 | 2024 | 4426 | 0.100 |
Why?
|
src-Family Kinases | 2 | 2017 | 539 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2145 | 0.100 |
Why?
|
Ribosomal Proteins | 1 | 2014 | 369 | 0.100 |
Why?
|
Disease Management | 5 | 2021 | 2533 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 8637 | 0.100 |
Why?
|
Mice, Inbred NOD | 5 | 2016 | 1837 | 0.100 |
Why?
|
Drug Eruptions | 1 | 2015 | 335 | 0.100 |
Why?
|
Fertility | 1 | 2016 | 771 | 0.100 |
Why?
|
Alternative Splicing | 2 | 2014 | 1104 | 0.100 |
Why?
|
Single-Cell Analysis | 2 | 2021 | 2543 | 0.100 |
Why?
|
Specimen Handling | 2 | 2013 | 708 | 0.100 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2016 | 1168 | 0.090 |
Why?
|
Receptors, Cytokine | 2 | 2009 | 258 | 0.090 |
Why?
|
Embryo, Nonmammalian | 1 | 1995 | 910 | 0.090 |
Why?
|
Disease Progression | 5 | 2023 | 13665 | 0.090 |
Why?
|
Animals | 33 | 2022 | 169222 | 0.090 |
Why?
|
Affect | 1 | 2019 | 1495 | 0.090 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 952 | 0.090 |
Why?
|
Fatal Outcome | 3 | 2018 | 1836 | 0.090 |
Why?
|
Community Networks | 1 | 2013 | 202 | 0.090 |
Why?
|
Physician Assistants | 1 | 2013 | 190 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 998 | 0.090 |
Why?
|
Transplantation, Autologous | 3 | 2011 | 2120 | 0.090 |
Why?
|
Time Factors | 12 | 2018 | 40214 | 0.090 |
Why?
|
Maytansine | 1 | 2011 | 88 | 0.090 |
Why?
|
Lymphadenitis | 1 | 2011 | 99 | 0.090 |
Why?
|
Drug Approval | 1 | 2017 | 820 | 0.090 |
Why?
|
Skin | 2 | 2018 | 4503 | 0.090 |
Why?
|
Central Nervous System | 1 | 2017 | 1346 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 2 | 2017 | 2055 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2014 | 563 | 0.090 |
Why?
|
Gene Expression Profiling | 10 | 2019 | 9536 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1141 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10396 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3886 | 0.080 |
Why?
|
DNA Mutational Analysis | 5 | 2020 | 4114 | 0.080 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 283 | 0.080 |
Why?
|
Blast Crisis | 2 | 2024 | 102 | 0.080 |
Why?
|
Inflammation Mediators | 2 | 2021 | 1892 | 0.080 |
Why?
|
Prednisone | 1 | 2014 | 1567 | 0.080 |
Why?
|
Child | 15 | 2024 | 80906 | 0.080 |
Why?
|
Neoplasm Staging | 5 | 2020 | 11221 | 0.080 |
Why?
|
Ubiquitins | 1 | 2011 | 366 | 0.080 |
Why?
|
Interleukin-2 | 2 | 2013 | 1895 | 0.080 |
Why?
|
Antigens | 1 | 2015 | 1442 | 0.080 |
Why?
|
RNA Splicing | 1 | 2013 | 905 | 0.080 |
Why?
|
Retreatment | 2 | 2021 | 598 | 0.080 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2009 | 892 | 0.080 |
Why?
|
Mutagenesis, Site-Directed | 3 | 2018 | 1683 | 0.080 |
Why?
|
Combinatorial Chemistry Techniques | 1 | 2009 | 136 | 0.080 |
Why?
|
RNA Interference | 6 | 2015 | 2830 | 0.080 |
Why?
|
Molecular Biology | 2 | 2023 | 573 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1365 | 0.080 |
Why?
|
Candidiasis | 1 | 2011 | 367 | 0.080 |
Why?
|
Liver | 3 | 2017 | 7574 | 0.080 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 2008 | 38 | 0.080 |
Why?
|
Quality of Life | 6 | 2023 | 13489 | 0.080 |
Why?
|
Candida albicans | 1 | 2011 | 375 | 0.080 |
Why?
|
JC Virus | 1 | 2008 | 87 | 0.070 |
Why?
|
Genomics | 4 | 2019 | 5925 | 0.070 |
Why?
|
RNA, Small Interfering | 5 | 2017 | 3428 | 0.070 |
Why?
|
Serotonin Antagonists | 1 | 2008 | 147 | 0.070 |
Why?
|
Diagnosis, Differential | 5 | 2019 | 13000 | 0.070 |
Why?
|
Enzyme Activation | 4 | 2006 | 3587 | 0.070 |
Why?
|
Intensive Care Units | 2 | 2019 | 3800 | 0.070 |
Why?
|
Hospitalization | 2 | 2019 | 10840 | 0.070 |
Why?
|
Platelet Count | 2 | 2024 | 787 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2007 | 82 | 0.070 |
Why?
|
Anticoagulants | 3 | 2020 | 4854 | 0.070 |
Why?
|
Alu Elements | 1 | 2007 | 115 | 0.070 |
Why?
|
Cell Survival | 6 | 2016 | 5772 | 0.070 |
Why?
|
Neutrophils | 2 | 2017 | 3786 | 0.070 |
Why?
|
Genetic Variation | 2 | 2021 | 6611 | 0.070 |
Why?
|
Interleukin-3 | 2 | 2005 | 425 | 0.070 |
Why?
|
Drug Costs | 1 | 2015 | 1195 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2018 | 2783 | 0.070 |
Why?
|
Mutation, Missense | 2 | 2006 | 2592 | 0.070 |
Why?
|
alpha Catenin | 1 | 2006 | 37 | 0.070 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2008 | 211 | 0.070 |
Why?
|
Peptide Fragments | 3 | 2014 | 5151 | 0.070 |
Why?
|
Propensity Score | 1 | 2014 | 1970 | 0.070 |
Why?
|
mRNA Cleavage and Polyadenylation Factors | 2 | 2006 | 105 | 0.070 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2005 | 451 | 0.070 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2008 | 534 | 0.070 |
Why?
|
Gene Duplication | 1 | 2007 | 315 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5520 | 0.070 |
Why?
|
Joints | 1 | 2008 | 324 | 0.070 |
Why?
|
History, 21st Century | 2 | 2017 | 1572 | 0.070 |
Why?
|
Sacrum | 1 | 2008 | 274 | 0.070 |
Why?
|
Thrombocytopenia | 3 | 2013 | 1179 | 0.070 |
Why?
|
Myeloid Progenitor Cells | 1 | 2006 | 112 | 0.070 |
Why?
|
Patient Participation | 1 | 2015 | 1446 | 0.070 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2006 | 178 | 0.060 |
Why?
|
Synovial Fluid | 1 | 2008 | 393 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 1889 | 0.060 |
Why?
|
Isochromosomes | 1 | 2005 | 16 | 0.060 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2009 | 614 | 0.060 |
Why?
|
Whole-Body Irradiation | 1 | 2006 | 435 | 0.060 |
Why?
|
Sea Urchins | 3 | 1995 | 45 | 0.060 |
Why?
|
Polyethylene Glycols | 1 | 2011 | 1196 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2017 | 3472 | 0.060 |
Why?
|
Drug Design | 2 | 2011 | 1045 | 0.060 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2005 | 55 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2017 | 4564 | 0.060 |
Why?
|
Idarubicin | 2 | 2019 | 59 | 0.060 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2005 | 127 | 0.060 |
Why?
|
Mice, Inbred BALB C | 5 | 2017 | 6231 | 0.060 |
Why?
|
Drug Monitoring | 3 | 2011 | 964 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1760 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5349 | 0.060 |
Why?
|
Risk | 2 | 2015 | 9609 | 0.060 |
Why?
|
Fatigue | 4 | 2017 | 1557 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 263 | 0.060 |
Why?
|
Comorbidity | 4 | 2015 | 10590 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7470 | 0.060 |
Why?
|
Liposomes | 1 | 2008 | 790 | 0.060 |
Why?
|
Vaccination | 1 | 2016 | 3437 | 0.060 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2005 | 285 | 0.060 |
Why?
|
Genes, myc | 1 | 2005 | 391 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 142 | 0.060 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 183 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5861 | 0.060 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2004 | 194 | 0.060 |
Why?
|
Pyridines | 3 | 2015 | 2893 | 0.060 |
Why?
|
Myeloablative Agonists | 1 | 2004 | 210 | 0.060 |
Why?
|
Zygote | 2 | 1995 | 117 | 0.050 |
Why?
|
Receptors, Colony-Stimulating Factor | 1 | 2023 | 51 | 0.050 |
Why?
|
Receptors, Notch | 1 | 2008 | 751 | 0.050 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3237 | 0.050 |
Why?
|
Transcription, Genetic | 3 | 2009 | 7612 | 0.050 |
Why?
|
Drug Synergism | 3 | 2015 | 1760 | 0.050 |
Why?
|
Antigens, CD | 2 | 2011 | 4035 | 0.050 |
Why?
|
Tissue Distribution | 3 | 2013 | 2299 | 0.050 |
Why?
|
Boronic Acids | 3 | 2013 | 915 | 0.050 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 482 | 0.050 |
Why?
|
Colony-Stimulating Factors | 1 | 2023 | 218 | 0.050 |
Why?
|
Terminal Care | 1 | 2015 | 1770 | 0.050 |
Why?
|
Recombinant Proteins | 4 | 2013 | 6515 | 0.050 |
Why?
|
Plasma | 1 | 2006 | 584 | 0.050 |
Why?
|
Renal Insufficiency | 1 | 2009 | 812 | 0.050 |
Why?
|
Consensus | 1 | 2013 | 3210 | 0.050 |
Why?
|
Dendritic Cells | 2 | 2023 | 2745 | 0.050 |
Why?
|
Arthritis | 1 | 2008 | 684 | 0.050 |
Why?
|
STAT Transcription Factors | 2 | 2018 | 189 | 0.050 |
Why?
|
Recombination, Genetic | 2 | 2007 | 1525 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
Antifungal Agents | 2 | 2022 | 761 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2024 | 2953 | 0.050 |
Why?
|
Cytokines | 3 | 2013 | 7450 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2016 | 2014 | 0.050 |
Why?
|
Transcription Factors | 3 | 2017 | 12165 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 438 | 0.050 |
Why?
|
Janus Kinases | 2 | 2018 | 253 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 1743 | 0.050 |
Why?
|
E-Selectin | 1 | 2024 | 577 | 0.050 |
Why?
|
RNA, Messenger | 6 | 2015 | 12797 | 0.050 |
Why?
|
Transplantation Chimera | 1 | 2004 | 594 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 2 | 2006 | 1966 | 0.050 |
Why?
|
Base Sequence | 5 | 2007 | 12418 | 0.050 |
Why?
|
Hodgkin Disease | 1 | 2009 | 1383 | 0.050 |
Why?
|
Pyrazines | 3 | 2013 | 1205 | 0.050 |
Why?
|
Phosphoproteins | 2 | 2024 | 2450 | 0.050 |
Why?
|
bcl-Associated Death Protein | 2 | 2015 | 102 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 3231 | 0.050 |
Why?
|
Point Mutation | 1 | 2006 | 1594 | 0.050 |
Why?
|
Retinal Neoplasms | 1 | 2003 | 151 | 0.050 |
Why?
|
Pharmaceutical Preparations | 1 | 2009 | 1086 | 0.040 |
Why?
|
Societies, Medical | 3 | 2019 | 3966 | 0.040 |
Why?
|
Histocompatibility | 1 | 2002 | 321 | 0.040 |
Why?
|
Gene Amplification | 1 | 2005 | 1088 | 0.040 |
Why?
|
Furans | 2 | 2015 | 199 | 0.040 |
Why?
|
Cells, Cultured | 5 | 2019 | 19017 | 0.040 |
Why?
|
Cohort Studies | 6 | 2024 | 41749 | 0.040 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2001 | 432 | 0.040 |
Why?
|
Isoquinolines | 2 | 2016 | 354 | 0.040 |
Why?
|
Molecular Sequence Data | 5 | 2007 | 17617 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2002 | 605 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2016 | 719 | 0.040 |
Why?
|
Protein Isoforms | 2 | 2018 | 1715 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2022 | 12536 | 0.040 |
Why?
|
Prospective Studies | 9 | 2023 | 54924 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2022 | 912 | 0.040 |
Why?
|
Piperidines | 1 | 2008 | 1667 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 681 | 0.040 |
Why?
|
Genomic Instability | 2 | 2015 | 716 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2230 | 0.040 |
Why?
|
Hematologic Diseases | 2 | 2014 | 498 | 0.040 |
Why?
|
Logistic Models | 3 | 2019 | 13289 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2013 | 11068 | 0.040 |
Why?
|
Pulmonary Veno-Occlusive Disease | 1 | 2019 | 64 | 0.040 |
Why?
|
United States | 8 | 2022 | 73027 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13499 | 0.040 |
Why?
|
beta Catenin | 2 | 2018 | 1047 | 0.040 |
Why?
|
Expert Testimony | 1 | 2020 | 266 | 0.040 |
Why?
|
Genetic Markers | 1 | 2005 | 2602 | 0.040 |
Why?
|
History, 20th Century | 1 | 2006 | 2766 | 0.040 |
Why?
|
Genome-Wide Association Study | 2 | 2017 | 12795 | 0.040 |
Why?
|
Choice Behavior | 1 | 2004 | 848 | 0.040 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2018 | 118 | 0.040 |
Why?
|
Resource Allocation | 1 | 2020 | 354 | 0.040 |
Why?
|
Hematopoietic Stem Cells | 3 | 2021 | 3409 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2004 | 1801 | 0.040 |
Why?
|
World Health Organization | 1 | 2023 | 1328 | 0.040 |
Why?
|
Infant | 5 | 2021 | 36534 | 0.040 |
Why?
|
Hydrolases | 1 | 2018 | 146 | 0.040 |
Why?
|
HIV Infections | 1 | 2024 | 17569 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2018 | 412 | 0.040 |
Why?
|
Phosphorus | 1 | 2018 | 336 | 0.030 |
Why?
|
Antithrombins | 1 | 2020 | 294 | 0.030 |
Why?
|
Immunoglobulin M | 2 | 2014 | 1527 | 0.030 |
Why?
|
Clinical Competence | 1 | 2013 | 4857 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 4205 | 0.030 |
Why?
|
Body Mass Index | 3 | 2023 | 13053 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2017 | 145 | 0.030 |
Why?
|
Cloning, Molecular | 3 | 2005 | 4168 | 0.030 |
Why?
|
Adenosine Triphosphatases | 1 | 2021 | 842 | 0.030 |
Why?
|
Cell Line | 5 | 2014 | 15597 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 788 | 0.030 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2008 | 2816 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 878 | 0.030 |
Why?
|
Child, Preschool | 5 | 2021 | 42665 | 0.030 |
Why?
|
Multiple Myeloma | 2 | 2011 | 5196 | 0.030 |
Why?
|
Dipeptides | 1 | 2018 | 386 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2017 | 14486 | 0.030 |
Why?
|
Anxiety | 2 | 2023 | 4672 | 0.030 |
Why?
|
Pityriasis | 1 | 2015 | 10 | 0.030 |
Why?
|
Chloramphenicol O-Acetyltransferase | 2 | 1993 | 221 | 0.030 |
Why?
|
Proteomics | 1 | 2009 | 3912 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 18062 | 0.030 |
Why?
|
Allergens | 1 | 2023 | 1434 | 0.030 |
Why?
|
Folliculitis | 1 | 2015 | 25 | 0.030 |
Why?
|
Hyperuricemia | 1 | 2018 | 222 | 0.030 |
Why?
|
Thiazolidinediones | 1 | 1998 | 460 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 19 | 0.030 |
Why?
|
Ichthyosis | 1 | 2015 | 59 | 0.030 |
Why?
|
Antigens, Neoplasm | 2 | 2016 | 1997 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12075 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2015 | 2884 | 0.030 |
Why?
|
Cytoprotection | 1 | 2015 | 199 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2456 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15944 | 0.030 |
Why?
|
Longitudinal Studies | 3 | 2019 | 14783 | 0.030 |
Why?
|
Mice, Nude | 2 | 2017 | 3620 | 0.030 |
Why?
|
Mice, Inbred C57BL | 4 | 2015 | 22381 | 0.030 |
Why?
|
Hydroxyurea | 1 | 2015 | 284 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3773 | 0.030 |
Why?
|
Europe | 2 | 2013 | 3437 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 182 | 0.030 |
Why?
|
Gene Knock-In Techniques | 1 | 2015 | 422 | 0.030 |
Why?
|
Paraproteins | 1 | 2014 | 38 | 0.030 |
Why?
|
Minority Groups | 1 | 2021 | 1217 | 0.030 |
Why?
|
Capillaries | 1 | 2017 | 756 | 0.030 |
Why?
|
Survivors | 1 | 2005 | 2381 | 0.030 |
Why?
|
Eukaryotic Initiation Factor-3 | 1 | 2014 | 47 | 0.030 |
Why?
|
Disease Models, Animal | 5 | 2017 | 18344 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1793 | 0.030 |
Why?
|
Cell Shape | 1 | 2015 | 371 | 0.030 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 1998 | 861 | 0.030 |
Why?
|
Models, Biological | 3 | 2019 | 9493 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 361 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 2004 | 5505 | 0.030 |
Why?
|
Alkylating Agents | 1 | 2014 | 132 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 711 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2018 | 2487 | 0.030 |
Why?
|
Antimetabolites | 1 | 2014 | 128 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1995 | 705 | 0.030 |
Why?
|
Drug Resistance | 2 | 2014 | 1598 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2008 | 3187 | 0.030 |
Why?
|
Nitrophenols | 1 | 2013 | 169 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2005 | 13420 | 0.030 |
Why?
|
Safety | 1 | 2018 | 1159 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 3601 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2018 | 22287 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2906 | 0.030 |
Why?
|
Creatinine | 1 | 2018 | 1918 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 1731 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 617 | 0.030 |
Why?
|
Oligonucleotides | 2 | 1993 | 563 | 0.030 |
Why?
|
Biopsy | 2 | 2018 | 6786 | 0.030 |
Why?
|
Multiple Organ Failure | 1 | 2015 | 388 | 0.030 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2012 | 94 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2016 | 620 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2017 | 800 | 0.020 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 359 | 0.020 |
Why?
|
Microinjections | 1 | 1993 | 319 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2005 | 4937 | 0.020 |
Why?
|
Length of Stay | 2 | 2018 | 6495 | 0.020 |
Why?
|
Overweight | 1 | 2023 | 2448 | 0.020 |
Why?
|
Coronary Thrombosis | 1 | 1995 | 440 | 0.020 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 318 | 0.020 |
Why?
|
Ilium | 1 | 2012 | 155 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1209 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 4282 | 0.020 |
Why?
|
Hematopoiesis | 2 | 2015 | 2059 | 0.020 |
Why?
|
Blastocyst | 1 | 1995 | 433 | 0.020 |
Why?
|
Cell Division | 3 | 2006 | 4473 | 0.020 |
Why?
|
Technology, Pharmaceutical | 1 | 2012 | 84 | 0.020 |
Why?
|
DNA Repair | 1 | 2021 | 2050 | 0.020 |
Why?
|
Sternum | 1 | 2012 | 177 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1605 | 0.020 |
Why?
|
Peripheral Nervous System | 1 | 2012 | 151 | 0.020 |
Why?
|
Binding, Competitive | 1 | 1993 | 1142 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2396 | 0.020 |
Why?
|
Secondary Prevention | 2 | 2010 | 1474 | 0.020 |
Why?
|
Stomatitis | 1 | 2014 | 271 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 799 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2013 | 435 | 0.020 |
Why?
|
Molecular Sequence Annotation | 1 | 2013 | 527 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8888 | 0.020 |
Why?
|
Depression | 2 | 2023 | 8231 | 0.020 |
Why?
|
Bronchial Spasm | 1 | 2011 | 71 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3589 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2015 | 605 | 0.020 |
Why?
|
Antibody Specificity | 1 | 1993 | 1065 | 0.020 |
Why?
|
Fluconazole | 1 | 2011 | 156 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 696 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1698 | 0.020 |
Why?
|
Inverted Repeat Sequences | 1 | 2010 | 59 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1995 | 2748 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2011 | 297 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 615 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3941 | 0.020 |
Why?
|
Histone Deacetylase 2 | 1 | 2010 | 72 | 0.020 |
Why?
|
Cell Count | 1 | 2014 | 1831 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3798 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2019 | 4289 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1150 | 0.020 |
Why?
|
Histone Deacetylase 1 | 1 | 2010 | 133 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1641 | 0.020 |
Why?
|
Physician-Patient Relations | 2 | 2018 | 3269 | 0.020 |
Why?
|
Permeability | 1 | 2011 | 725 | 0.020 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2015 | 616 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8740 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5624 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2010 | 161 | 0.020 |
Why?
|
Decision Making | 2 | 2018 | 3952 | 0.020 |
Why?
|
Up-Regulation | 1 | 2018 | 4146 | 0.020 |
Why?
|
Harringtonines | 1 | 2008 | 8 | 0.020 |
Why?
|
Drugs, Investigational | 1 | 2011 | 211 | 0.020 |
Why?
|
Muramidase | 1 | 2009 | 163 | 0.020 |
Why?
|
Fluorouracil | 1 | 2014 | 1652 | 0.020 |
Why?
|
Spleen | 2 | 2006 | 2295 | 0.020 |
Why?
|
DNA Replication | 1 | 2015 | 1427 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3414 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2013 | 1230 | 0.020 |
Why?
|
Farnesyltranstransferase | 1 | 2008 | 71 | 0.020 |
Why?
|
Emergencies | 1 | 1995 | 1224 | 0.020 |
Why?
|
Cell Death | 1 | 2013 | 1679 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 1441 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1134 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 1244 | 0.020 |
Why?
|
Genes, abl | 1 | 2008 | 69 | 0.020 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 1995 | 1724 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1395 | 0.020 |
Why?
|
Africa | 1 | 2010 | 725 | 0.020 |
Why?
|
HeLa Cells | 1 | 2014 | 3074 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 886 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2014 | 1752 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2015 | 7876 | 0.020 |
Why?
|
Palliative Care | 2 | 2016 | 3642 | 0.020 |
Why?
|
Metabolomics | 1 | 2017 | 1674 | 0.020 |
Why?
|
Risk Assessment | 3 | 2018 | 24314 | 0.020 |
Why?
|
Oxazines | 1 | 2009 | 358 | 0.020 |
Why?
|
Fibrinogen | 1 | 2010 | 891 | 0.020 |
Why?
|
Diarrhea | 1 | 2014 | 1320 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2008 | 287 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2574 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2014 | 2731 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 2014 | 2094 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3271 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3813 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1998 | 2540 | 0.020 |
Why?
|
Morpholines | 1 | 2009 | 584 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9368 | 0.020 |
Why?
|
Pharmacokinetics | 1 | 2006 | 86 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1434 | 0.020 |
Why?
|
Binding Sites | 1 | 1995 | 6022 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2015 | 20218 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 2007 | 1305 | 0.020 |
Why?
|
Immunotoxins | 1 | 2006 | 175 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2006 | 351 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1326 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2011 | 863 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1890 | 0.020 |
Why?
|
Gene Library | 1 | 2008 | 1065 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3618 | 0.020 |
Why?
|
Immunoblotting | 1 | 2009 | 1647 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2008 | 748 | 0.020 |
Why?
|
Tyrphostins | 1 | 2005 | 62 | 0.020 |
Why?
|
Chromosome Banding | 1 | 2005 | 261 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7597 | 0.020 |
Why?
|
Butadienes | 1 | 2005 | 107 | 0.020 |
Why?
|
Models, Genetic | 2 | 2007 | 3447 | 0.020 |
Why?
|
Cell Cycle | 1 | 2013 | 2932 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6411 | 0.020 |
Why?
|
Calcium | 1 | 2018 | 5794 | 0.020 |
Why?
|
Tyrosine | 1 | 2009 | 1427 | 0.020 |
Why?
|
Protein Conformation | 1 | 1993 | 3956 | 0.020 |
Why?
|
Genetic Vectors | 2 | 2006 | 3402 | 0.020 |
Why?
|
K562 Cells | 1 | 2006 | 644 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2011 | 1443 | 0.010 |
Why?
|
Age Distribution | 1 | 2011 | 2871 | 0.010 |
Why?
|
Carbazoles | 1 | 2006 | 230 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1993 | 4618 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3701 | 0.010 |
Why?
|
Histone Deacetylases | 1 | 2009 | 717 | 0.010 |
Why?
|
Tissue Donors | 2 | 2006 | 2381 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 2004 | 194 | 0.010 |
Why?
|
Cell Fusion | 1 | 2004 | 294 | 0.010 |
Why?
|
Eye | 1 | 2008 | 712 | 0.010 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2004 | 192 | 0.010 |
Why?
|
Cell Nucleus | 1 | 1993 | 2881 | 0.010 |
Why?
|
Hydrogen Bonding | 1 | 2004 | 289 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9666 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2014 | 2982 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3110 | 0.010 |
Why?
|
Central Nervous System Neoplasms | 1 | 2012 | 928 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2008 | 724 | 0.010 |
Why?
|
Phosphotyrosine | 1 | 2004 | 458 | 0.010 |
Why?
|
Hospitals, General | 1 | 2008 | 806 | 0.010 |
Why?
|
Blood Cell Count | 1 | 2004 | 406 | 0.010 |
Why?
|
Graft Survival | 2 | 2006 | 3887 | 0.010 |
Why?
|
Exanthema | 1 | 2008 | 502 | 0.010 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2004 | 259 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6283 | 0.010 |
Why?
|
Tandem Mass Spectrometry | 1 | 2009 | 1197 | 0.010 |
Why?
|
Stents | 1 | 1995 | 3195 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3669 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2016 | 3114 | 0.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2006 | 496 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2016 | 4791 | 0.010 |
Why?
|
Retinal Hemorrhage | 1 | 2003 | 98 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 816 | 0.010 |
Why?
|
Drug Hypersensitivity | 1 | 2011 | 903 | 0.010 |
Why?
|
Zinc Fingers | 1 | 2004 | 577 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2008 | 1361 | 0.010 |
Why?
|
Cell Movement | 1 | 2014 | 5209 | 0.010 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2003 | 377 | 0.010 |
Why?
|
Protein Binding | 1 | 2014 | 9343 | 0.010 |
Why?
|
Serine | 1 | 2005 | 831 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 4904 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15442 | 0.010 |
Why?
|
Topotecan | 1 | 2001 | 131 | 0.010 |
Why?
|
Antigen-Presenting Cells | 1 | 2005 | 960 | 0.010 |
Why?
|
Liver Diseases | 1 | 2009 | 1305 | 0.010 |
Why?
|
Green Fluorescent Proteins | 1 | 2006 | 2065 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 13091 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2004 | 1353 | 0.010 |
Why?
|
Fever | 1 | 2008 | 1613 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 1998 | 6371 | 0.010 |
Why?
|
Retroviridae | 1 | 2003 | 846 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2054 | 0.010 |
Why?
|
Coronary Disease | 1 | 1995 | 5919 | 0.010 |
Why?
|
DNA Primers | 1 | 2005 | 2827 | 0.010 |
Why?
|
Dyspnea | 1 | 2008 | 1352 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6211 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8748 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2008 | 1207 | 0.010 |
Why?
|
Lung Diseases | 1 | 2009 | 1944 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2736 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2008 | 2211 | 0.010 |
Why?
|
Necrosis | 1 | 2003 | 1616 | 0.010 |
Why?
|
Patient Readmission | 1 | 2013 | 3288 | 0.010 |
Why?
|
Transfection | 1 | 2006 | 5757 | 0.010 |
Why?
|
Pain | 1 | 2014 | 5100 | 0.010 |
Why?
|
Chromans | 1 | 1998 | 116 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2005 | 1492 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 6071 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2013 | 4310 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2004 | 3096 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16723 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2006 | 1671 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2008 | 5314 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 3771 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2004 | 1667 | 0.010 |
Why?
|
Heart Diseases | 1 | 2009 | 2819 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2010 | 20757 | 0.010 |
Why?
|
Reoperation | 1 | 2006 | 4329 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2008 | 2195 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2009 | 12464 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 4785 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2001 | 1308 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 30260 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 4915 | 0.010 |
Why?
|
Models, Molecular | 1 | 2004 | 5402 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1995 | 11519 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 7065 | 0.010 |
Why?
|
Visual Acuity | 1 | 2003 | 2714 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6668 | 0.010 |
Why?
|
Coronary Aneurysm | 1 | 1995 | 234 | 0.010 |
Why?
|
Genome, Human | 1 | 2005 | 4443 | 0.010 |
Why?
|
Ligands | 1 | 1998 | 3284 | 0.010 |
Why?
|
Algorithms | 1 | 2011 | 14163 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2011 | 26420 | 0.010 |
Why?
|
Simian virus 40 | 1 | 1989 | 292 | 0.000 |
Why?
|
Deoxyribonuclease I | 1 | 1989 | 228 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11930 | 0.000 |
Why?
|
Chronic Disease | 1 | 2003 | 9384 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 2002 | 14718 | 0.000 |
Why?
|
Coronary Angiography | 1 | 1995 | 4541 | 0.000 |
Why?
|
Promoter Regions, Genetic | 1 | 1989 | 5798 | 0.000 |
Why?
|